Leading risk factors, causes of death underrepresented in NIH-supported prevention research

November 08, 2019

What:

A study by National Institutes of Health scientists in the Office of Disease Prevention (ODP) examined NIH grants and cooperative agreements during fiscal years 2012 through 2017 to determine the alignment of prevention research across NIH institutes and centers with leading risk factors and causes of death and disability in the United States. The study found that while the top-10 risk factors for death are associated with more than half of the deaths in the United States, only a third of NIH-supported prevention research measured those risk factors as exposures or outcomes. Similarly, while 7 out of every 10 Americans die from the 10 leading causes of death, fewer than 3 in 10 prevention research projects supported by the NIH measure these causes of death as exposures or outcomes. The study was published today in the journal JAMA Network Open.

The study revealed that most prevention research projects included an observational design or secondary data analysis, while relatively few included a clinical trial focused on preventing the leading risk factors and causes for death. Further, even though it is common for one person to have multiple risk factors (e.g., individuals who smoke also often have a poor diet and engage in little physical activity), few studies took advantage of this pattern to address multiple risk factors at the same time.

The analysis was limited by sampling only the most common types of grant awards and examining only primary and secondary prevention research in humans. The analysis excluded basic, pre-clinical, and clinical research that might eventually lead to prevention research.

This report suggests there is an opportunity for the NIH to better align prevention research with the leading causes and risk factors for death and disability in the United States, particularly by incorporating more clinical trials to evaluate interventions to prevent those risk factors and causes.
-end-
Article:

Vargas, A.J., Schully, S.D., Villani, J., Ganoza Caballero, L., Murray, D.M., "Assessment of Prevention Research Measuring Leading Risk Factors and causes of Mortality and Disability Supported by the U.S. National Institutes of Health" JAMA Network Open DOI: 10.1001/jamanetworkopen.2019.14718 (Nov. 8, 2019).

Who:Contact:

To schedule an interview, please contact Kat Schwartz, odpmedia@od.nih.gov, 301-827-6541.

About the Office of Disease Prevention (ODP): The ODP is the lead office at the NIH responsible for assessing, facilitating, and stimulating research in disease prevention, and disseminating the results of this research to improve public health. For more information about the ODP, visit prevention.nih.gov.

NIH/Office of the Director

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.